4//SEC Filing
Eldridge George A 4
Accession 0001415889-24-007534
CIK 0001798749other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 6:00 PM ET
Size
23.8 KB
Accession
0001415889-24-007534
Insider Transaction Report
Form 4
Eldridge George A
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-03-08$2.14/sh+114$244→ 2,074 total - Sale
Common Stock
2024-03-11$25.24/sh−3,423$86,404→ 1,970 total - Sale
Common Stock
2024-03-11$26.30/sh−10$263→ 1,960 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-08−114→ 58,763 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (114 underlying) - Exercise/Conversion
Common Stock
2024-03-07$2.14/sh+22,386$47,906→ 24,346 total - Sale
Common Stock
2024-03-07$25.00/sh−22,386$559,688→ 1,960 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-11−3,433→ 55,330 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (3,433 underlying) - Sale
Common Stock
2024-03-08$25.00/sh−114$2,850→ 1,960 total - Exercise/Conversion
Common Stock
2024-03-11$2.14/sh+3,433$7,347→ 5,393 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-07−20,986→ 58,877 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (20,986 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-07−1,400→ 28,263 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (1,400 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.289, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
- [F5]A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Documents
Issuer
Aerovate Therapeutics, Inc.
CIK 0001798749
Entity typeother
Related Parties
1- filerCIK 0001413006
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 6:00 PM ET
- Size
- 23.8 KB